These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 39216477)

  • 1. A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib.
    Simoni-Nieves A; Lindzen M; Giri S; Gupta N; Chatterjee R; Selvadurai BR; Van Daele M; Love D; Haga Y; Romaniello D; Salame TM; Zerbib M; Oren R; Tsutsumi Y; Lauriola M; Marrocco I; Yarden Y
    Cell Rep Med; 2024 Sep; 5(9):101703. PubMed ID: 39216477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
    Han R; Lu CH; Hu C; Dou YY; Kang J; Lin CY; Wu D; Jiang WL; Yin GQ; He Y
    Acta Pharmacol Sin; 2024 Jun; 45(6):1264-1275. PubMed ID: 38438582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
    Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
    Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
    Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
    Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
    Nakamura R; Yamada T; Tokuda S; Morimoto K; Katayama Y; Matsui Y; Hirai S; Ishida M; Kawachi H; Sawada R; Tachibana Y; Osoegawa A; Horinaka M; Sakai T; Yasuhiro T; Kozaki R; Yano S; Takayama K
    Cancer Lett; 2024 Aug; 598():217124. PubMed ID: 39059573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
    Taniguchi H; Yamada T; Wang R; Tanimura K; Adachi Y; Nishiyama A; Tanimoto A; Takeuchi S; Araujo LH; Boroni M; Yoshimura A; Shiotsu S; Matsumoto I; Watanabe S; Kikuchi T; Miura S; Tanaka H; Kitazaki T; Yamaguchi H; Mukae H; Uchino J; Uehara H; Takayama K; Yano S
    Nat Commun; 2019 Jan; 10(1):259. PubMed ID: 30651547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
    Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S
    Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways.
    Romaniello D; Mazzeo L; Mancini M; Marrocco I; Noronha A; Kreitman M; Srivastava S; Ghosh S; Lindzen M; Salame TM; Onn A; Bar J; Yarden Y
    Clin Cancer Res; 2018 Nov; 24(22):5610-5621. PubMed ID: 29967248
    [No Abstract]   [Full Text] [Related]  

  • 10. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
    Wang R; Yamada T; Kita K; Taniguchi H; Arai S; Fukuda K; Terashima M; Ishimura A; Nishiyama A; Tanimoto A; Takeuchi S; Ohtsubo K; Yamashita K; Yamano T; Yoshimura A; Takayama K; Kaira K; Taniguchi Y; Atagi S; Uehara H; Hanayama R; Matsumoto I; Han X; Matsumoto K; Wang W; Suzuki T; Yano S
    Nat Commun; 2020 Sep; 11(1):4607. PubMed ID: 32929081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
    Tanaka H; Sakagami H; Kaneko N; Konagai S; Yamamoto H; Matsuya T; Yuri M; Yamanaka Y; Mori M; Takeuchi M; Koshio H; Hirano M; Kuromitsu S
    Mol Cancer Ther; 2019 Aug; 18(8):1366-1373. PubMed ID: 31092564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.
    Park W; Wei S; Xie CL; Han JH; Kim BS; Kim B; Jin JS; Yang ES; Cho MK; Ryu D; Yang HX; Bae SJ; Ha KT
    Exp Mol Med; 2024 May; 56(5):1137-1149. PubMed ID: 38689087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
    Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG
    Nat Genet; 2012 Jul; 44(8):852-60. PubMed ID: 22751098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor-Tolerant Cells in NSCLC Patient-Derived Xenografts.
    Zhou CQ; Li A; Ri K; Sultan AS; Ren H
    Cancer Res Commun; 2024 Sep; 4(9):2308-2319. PubMed ID: 39041204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
    Yoshimura A; Yamada T; Serizawa M; Uehara H; Tanimura K; Okuma Y; Fukuda A; Watanabe S; Nishioka N; Takeda T; Chihara Y; Takemoto S; Harada T; Hiranuma O; Shirai Y; Shukuya T; Nishiyama A; Goto Y; Shiotsu S; Kunimasa K; Morimoto K; Katayama Y; Suda K; Mitsudomi T; Yano S; Kenmotsu H; Takahashi T; Takayama K
    Cancer Sci; 2023 Feb; 114(2):606-618. PubMed ID: 36169649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro.
    Nishino M; Suda K; Kobayashi Y; Ohara S; Fujino T; Koga T; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2018 Dec; 126():149-155. PubMed ID: 30527179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
    Uchibori K; Inase N; Araki M; Kamada M; Sato S; Okuno Y; Fujita N; Katayama R
    Nat Commun; 2017 Mar; 8():14768. PubMed ID: 28287083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
    Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer.
    Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun SY
    J Exp Med; 2024 Nov; 221(11):. PubMed ID: 39297884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.